Duygu Vezir

Duygu Vezir


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YAYunus Emre emre Ayhan
Yunus Emre emre Ayhan
MAMüzeyyen Aksoy
Müzeyyen Aksoy
YAYahya Abdulrahman
Yahya Abdulrahman
ZEZeynep Safiye Şahin Eröksüz
Zeynep Safiye Şahin Eröksüz
DVDuygu Vezir
Duygu Vezir
MSMesut Sancar
Mesut Sancar
Background: Pulmonary embolism (PE) poses significant morbidity and mortality risks, necessitating tailored anticoagulant therapy. Limited studies investigate the drug-related problems (DRPs) in PE. This study aims to evaluate the impact of clinical pharmacist (CP) interventions on drug-related problems (DRPs) and clinical outcomes in outpatients with PE. By addressing DRPs in this specific population, the study seeks to assess the role of CP-led interventions in enhancing patient safety and optimizing treatment outcomes. Methods: A randomized controlled trial was conducted on PE patients at a pulmonology outpatient clinic over the period of 15 January 2022 to January 2023. In this trial, the intervention group (IG) benefited from CP recommendations targeting DRPs, while the control group (CG) was observed without any additional interventions. Follow-ups were conducted at 90 and 180 days post-discharge. The study focused on DRPs, CP interventions, and patient outcomes. Data were systematically recorded and analyzed, adhering to ethical standards and employing the PCNE v9.1 classification system. Results: The study followed 50 PE patients, with 26 in the IG and 24 in the CG. DRPs, mostly in drug and dose selection, affected 84% of participants (3.34 DRPs/patient). In the IG, the CP made 76 recommendations (91.5%) for 83 DRPs at the prescribing physician level. Majority of these recommendations (94.7%) were accepted. At the 90-day follow-up, bleeding occurred in 16.6% of the CG, with none in the IG (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.654–3.198, p = 0.046). As indicated by Cramér’s V (0.307), the effect size demonstrated a moderate association between the intervention and the absence of bleeding events in the IG. At the 180-day follow-up, bleeding was 33.3% in the CG and 16.6% in the IG (p = 0.443). Conclusions: PE patients experience common and frequent DRPs, especially in anticoagulation therapy. CP recommendations are widely accepted but need to be better implemented. No bleeding events were observed in the IG where a CP was involved at 90 days, unlike the CG. Including a CP in the PE treatment team seems to influence outcomes positively.

19 August 2024 in Life
Verified
Journal Article
Open access
PDF file
BBBaran Balcan
Baran Balcan
DVDuygu Vezir
Duygu Vezir
SYSehnaz Olgun yildizeli
Sehnaz Olgun yildizeli
DKDerya Kocakaya
Derya Kocakaya
BCBerrin Ceyhan
Berrin Ceyhan
Obstructive sleep apnea (OSA) and cystic fibrosis (CF) are chronic conditions that profoundly impact quality of life. OSA, characterized by repeated episodes of upper airway collapse, can exacerbate CF symptoms due to nocturnal airway obstruction. Recent studies highlight the prevalence of OSA in CF patients, especially in adults, and its detrimental effects on health and quality of life. From April 2019 to December 2021, we conducted a study with 104 bronchiectasis patients at Marmara University Pendik Training and Research Hospital. After exclusions, 70 participants (35 CF and 35 non-CF) were included. Sleep parameters were assessed with polysomnography, and depressive mood was evaluated using the Zung Self-Rating Depression Scale (SDS). Daytime sleepiness was measured using the Epworth Sleepiness Scale (ESS). The statistical analyses included t-tests, chi-square tests, and logistic regression. Among the CF patients, depressive mood was significantly associated with female sex (OR: 4.28, 95% CI: 1.27–12.04) and anemia (OR: 7.87, 95% CI: 1.50–41.27). Higher ESS scores indicated greater daytime sleepiness in the depressive groups (p = 0.051). Depressive CF patients also had a significantly longer disease duration and more frequent annual exacerbations. No significant differences were found in total sleep time, sleep efficiency, or sleep stages between the depressive and non-depressive groups. A lower forced vital capacity (FVC) was observed in the depressive CF patients, although not significantly. Depression is prevalent among adult CF patients with OSA, with significant associations with female sex and anemia. These findings underscore the need for integrated care addressing both physical and mental health aspects, including interventions for respiratory symptoms, anemia management, and sleep quality enhancement to improve overall quality of life.

9 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BBBaran Balcan
Baran Balcan
DVDuygu Vezir
Duygu Vezir
RÖRamazan Öcal
Ramazan Öcal
CÇCaner Çınar
Caner Çınar
YCYeliz Celik
Yeliz Celik
BCBerrin Ceyhan
Berrin Ceyhan
(1) Background: Anemia and obstructive sleep apnea (OSA) are prevalent comorbidities in bronchiectasis and may share overlapping pathophysiological mechanisms. However, their combined impact on clinical outcomes in bronchiectasis remains underexplored. We aimed to investigate the associations between anemia, OSA, and clinical characteristics in patients with bronchiectasis, including cystic fibrosis (CF) and non-CF subtypes. (2) Methods: 70 adults with bronchiectasis (35 CF-related, 35 non-CF) underwent polysomnography. Anemia was defined using standard hemoglobin <13 g/dL for men and <12 g/dL for women. Clinical, nutritional, and sleep-related variables were assessed, and associations with anemia were evaluated. (3) Results: Anemia was present in 24.3% of participants. Compared to non-anemic patients, those with anemia had significantly higher rates of female sex (38.5% vs. 6.5%, p=0.002), nutritional problems (47.1% vs. 20.8%, p=0.034), OSA prevalence (94.1% vs. 54.7%, p=0.003), and annual hospitalizations (1.41 ± 0.41 vs. 0.43 ± 0.10, p=0.002). In multivariate analysis, female sex (OR: 12.32; 95% CI: 3.12 – 45.96; p=0.002) and OSA (OR: 4.70; 95% CI: 2.67 – 45.29; p=0.007) remained independent predictors of anemia. Subgroup analysis showed a significant univariate association between OSA and anemia in CF patients (p=0.045), while hospitalization frequency was an independent predictor of anemia in non-CF bronchiectasis (p=0.040). (4) Conclusions: Anemia in bronchiectasis is independently associated with female sex and OSA, with additional subgroup-specific associations. These findings suggest that OSA may contribute to the systemic burden of disease in bronchiectasis and highlight the importance of integrated management strategies.

17 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BBBaran Balcan
Baran Balcan
DVDuygu Vezir
Duygu Vezir
RÖRamazan Öcal
Ramazan Öcal
CÇCaner Çınar
Caner Çınar
EAErdal Aksoy
Erdal Aksoy
BCBerrin Ceyhan
Berrin Ceyhan
Background: Anemia and obstructive sleep apnea (OSA) are prevalent comorbidities in bronchiectasis and may share overlapping pathophysiological mechanisms. However, their combined impact on clinical outcomes in bronchiectasis remains underexplored. We aimed to investigate the associations between anemia, OSA, and clinical characteristics in patients with bronchiectasis, including cystic fibrosis (CF) and non-CF subtypes. Methods: 70 adults with bronchiectasis (35 CF-related, 35 non-CF) underwent polysomnography. Anemia was defined using standard hemoglobin < 13 g/dL for men and <12 g/dL for women. Clinical, nutritional, and sleep-related variables were assessed, and associations with anemia were evaluated. Results: Anemia was present in 24.3% of participants. Compared to non-anemic patients, those with anemia had significantly higher rates of female sex (38.5% vs. 6.5%, p = 0.002), nutritional problems (47.1% vs. 20.8%, p = 0.034), OSA prevalence (94.1% vs. 54.7%, p = 0.003), and annual hospitalizations (1.41 ± 0.41 vs. 0.43 ± 0.10, p = 0.002). In multivariate analysis, female sex (OR: 12.32; 95% CI: 3.12–45.96; p = 0.002) and OSA (OR: 4.70; 95% CI: 2.67–45.29; p = 0.007) remained independent predictors of anemia. Subgroup analysis showed a significant univariate association between OSA and anemia in CF patients (p = 0.045), while hospitalization frequency was an independent predictor of anemia in non-CF bronchiectasis (p = 0.040). Conclusions: Anemia in bronchiectasis is independently associated with female sex and OSA, with additional exploratory subgroup findings. These findings indicate an association between OSA and anemia within bronchiectasis populations; however, the cross-sectional design precludes conclusions regarding directionality or causality.